Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Healios KK Ord Shs > Some News Anyway. No Effect Though
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by waynedon Feb 09, 2012 9:20pm
207 Views
Post# 19513241

RE: Some News Anyway. No Effect Though

RE: Some News Anyway. No Effect Though

  Well Halo has been able to raise the bar even higher for sloth on the Vancouver exchange . Further to an announcement made in 2008 . Are you kidding me !? When do they plan to drill , in 2021 ? And now copper is back to $4 and what do we hear about our prolific Sheridan property . Well zipp of course . But I`ll bet you very soon there will be another financing . Got to make the big payroll somehow .

One of the biggest blunders I ever made was getting mixed up with these clowns . Anybody else ever try to contact them ? Even one of their three PR companies can`t bother to respond .

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities